Drug Type Small molecule drug |
Synonyms CTS 2190, CTS2190 |
Target |
Action inhibitors |
Mechanism PRMT1 inhibitors(Protein arginine N-methyltransferase 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Non-Small Cell Lung Cancer | Phase 2 | China | 26 Jun 2023 | |
| Pancreatic Cancer | Phase 2 | China | 26 Jun 2023 | |
| Triple Negative Breast Cancer | Phase 2 | China | 26 Jun 2023 | |
| Solid tumor | Phase 2 | China | 14 Jun 2023 | |
| Metastatic castration-resistant prostate cancer | Preclinical | China | 29 Apr 2025 |
Phase 1/2 | Solid tumor arginine methyltransferase 1 (PRMT1) | asymmetric dimethylarginine (ADMA) | DNA damage response (DDR) ... View more | 38 | vmdvaprtmv(pviglfvssy) = 31.6% vloixjqokd (bjgjyqosqy ) View more | Positive | 30 May 2025 | ||
NCT06224387 (ESMO2024) Manual | Phase 1/2 | 15 | CTS2190 60 mg | ujjoqrzvbp(xocweklyrk) = jhxxhppmra cvgdrjedwo (rysopnnsua ) View more | Positive | 14 Sep 2024 |





